P06 Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1–42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD. Issue 8 (August 2019) - Grimmer, T.; Rabe, C.; Navarro, M.; Clayton, D.; Manuilova, E.; Peters, O.; Eichenlaub, U.; Smith, J.; Ostrowitzki, S.; Honigberg, L.; Bittner, T.